AMO unveils new silicone Tecnis IOL

Article

Advanced Medical Optics (AMO) announced the launch of the Tecnis CL intraocular lens (IOL) at the XXIV congress of the ESCRS.

Advanced Medical Optics (AMO) announced the launch of the Tecnis CL intraocular lens (IOL) at the XXIV congress of the ESCRS.

The new lens features blue modified C PMMA haptics for improved visibility and easier implantation, frosted OptiEdge design for reduced edge glare and reduced posterior capsule opacification and highly biocompatible silicone. The Tecnis CL can be implanted using the UNFOLDER Silver Series Implantation Systems and the Silver Advanced Cartridge through a 2.8 mm incision.

The new lens acts as a permanent replacement to the Z9000 and Z9001 Tecnis silicone IOL models.

In August of this year, the US Centers for Medicare and Medicaid Services (CMS) extended New Technology Intraocular Lens (NTIOL) status to the lens. Tecnis and Tecnis CL are the only FDA approved IOLs that are indicated for reducing spherical equivalent, improving visual function and improving night driving performance.

The Tecnis CL is now available in Europe and AMO intends to start shipping the lens to the US, Canada and Asia Pacific within the next month and to Japan by mid-2007.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.